# A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

> **NCT06466785** · PHASE3 · RECRUITING · sponsor: **Genexine, Inc.** · enrollment: 429 (estimated)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **DRUG:** Efepoetin Alfa
- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT06466785
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2026-12
- **Final completion:** 2027-09
- **Target enrollment:** 429 (ESTIMATED)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06466785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06466785, "A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06466785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*